AIM: This study investigated the impact of the circulating galectin-3 level on the 30-day prognostic outcome in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). METHODS: From May 2009 to March 2011, blood samples for assessment of the circulating galectin-3 level were collected from 196 consecutive STEMI patients treated by primary PCI and from 30 healthy volunteers. RESULTS: The galectin-3 level was determined using ELISA. Our results demonstrated that the circulating level of galectin-3 was significantly higher in STEMI patients than in healthy control subjects (p<0.001). As compared with patients with galectin-3 <7.67 ng/mL, patients with galectin-3 ≥7.67 ng/mL were significantly older, had significantly lower left ventricular ejection fraction and significantly higher frequency of elevated white blood cell count, advanced Killip score (defined as ≥ score 3), congestive heart failure (defined as ≥ New York Heart Association Functional Class III), respiratory failure, unstable hemodynamics requiring a mechanical ventilator and intra-aortic balloon pump support, multiple vessel diseases and 30-day mortality (all p<0.04). Furthermore, multivariate analysis showed that elevated circulating level of galectin-3 was the strongest independent predictor of the combined 30-day major adverse clinical outcome (MACO) (defined as advanced CHF or 30-day mortality) (p<0.0001). CONCLUSION: A high circulating galectin-3 level may serve as a useful biomarker for predicting 30-day MACO in patients with STEMI undergoing primary PCI.
AIM: This study investigated the impact of the circulating galectin-3 level on the 30-day prognostic outcome in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). METHODS: From May 2009 to March 2011, blood samples for assessment of the circulating galectin-3 level were collected from 196 consecutive STEMI patients treated by primary PCI and from 30 healthy volunteers. RESULTS: The galectin-3 level was determined using ELISA. Our results demonstrated that the circulating level of galectin-3 was significantly higher in STEMI patients than in healthy control subjects (p<0.001). As compared with patients with galectin-3 <7.67 ng/mL, patients with galectin-3 ≥7.67 ng/mL were significantly older, had significantly lower left ventricular ejection fraction and significantly higher frequency of elevated white blood cell count, advanced Killip score (defined as ≥ score 3), congestive heart failure (defined as ≥ New York Heart Association Functional Class III), respiratory failure, unstable hemodynamics requiring a mechanical ventilator and intra-aortic balloon pump support, multiple vessel diseases and 30-day mortality (all p<0.04). Furthermore, multivariate analysis showed that elevated circulating level of galectin-3 was the strongest independent predictor of the combined 30-day major adverse clinical outcome (MACO) (defined as advanced CHF or 30-day mortality) (p<0.0001). CONCLUSION: A high circulating galectin-3 level may serve as a useful biomarker for predicting 30-day MACO in patients with STEMI undergoing primary PCI.
Authors: Umesh C Sharma; Wassim Mosleh; Milind R Chaudhari; Rujuta Katkar; Brian Weil; Chris Evelo; Thomas R Cimato; Saraswati Pokharel; W Matthijs Blankesteijn; Gen Suzuki Journal: Heart Lung Circ Date: 2016-12-19 Impact factor: 2.975
Authors: Rabea Asleh; Maurice Enriquez-Sarano; Allan S Jaffe; Sheila M Manemann; Susan A Weston; Ruoxiang Jiang; Véronique L Roger Journal: J Am Coll Cardiol Date: 2019-05-14 Impact factor: 24.094
Authors: Teresa Arias; Artiom Petrov; Jiqiu Chen; Hans de Haas; Carlos Pérez-Medina; Gustav J Strijkers; Roger J Hajjar; Zahi A Fayad; Valentín Fuster; Jagat Narula Journal: EJNMMI Res Date: 2014-12-14 Impact factor: 3.138
Authors: Alison C MacKinnon; Xiaojun Liu; Patrick Wf Hadoke; Mark R Miller; David E Newby; Tariq Sethi Journal: Glycobiology Date: 2013-02-19 Impact factor: 4.313
Authors: Yonggang Ma; Lisandra E de Castro Brás; Hiroe Toba; Rugmani Padmanabhan Iyer; Michael E Hall; Michael D Winniford; Richard A Lange; Suresh C Tyagi; Merry L Lindsey Journal: Pflugers Arch Date: 2014-02-13 Impact factor: 3.657